T-cell receptor–major histocompatibility complex–carcinoembryonic antigen complex

The "TCR/MHC-CEA complex" refers to a molecular assembly in which a **T-cell receptor (TCR)** on the surface of a T cell specifically recognizes a **peptide–major histocompatibility complex (pMHC)** that includes a peptide derived from **carcinoembryonic antigen (CEA)**. In this interaction, CEA peptides are presented on major histocompatibility complex (MHC) molecules on the surface of antigen-presenting cells (often tumor cells), which are in turn recognized by a specific TCR on T cells[1][3][5]. This ternary complex is central to antigen-specific immune recognition and T cell activation[2][7]. The TCR/pMHC interaction is fundamental in adaptive immunity, with the CEA peptide representing a tumor-associated antigen prevalent in various cancers[7][8]. This interaction is of great interest in tumor immunology and cancer immunotherapy, though "TCR/MHC-CEA complex" is an assembly or structure—not a canonical therapeutic target—since drugs and therapies most commonly target either the TCR, the MHC-peptide complex, or the CEA antigen individually, not the full complex[5][6][7]. Notably, the name "TCR/MHC-CEA complex" is not a canonical or standardized molecular target; it describes a functional interaction or structural complex rather than a single identifiable protein or receptor. There is no canonical abbreviation for this assembly, and it is not listed as a singular target in pharmacological or molecular databases. Therapeutic targeting strategies involving this axis are usually developed as TCR-engineered T cells specific for CEA-derived peptides displayed on MHC molecules[3][5]. The CEA protein itself is a well-known cancer biomarker and target of antibody- and T cell-based immunotherapies, but the full ternary complex is not itself a drug target. In summary, the "TCR/MHC-CEA complex" is not a canonical molecular target but rather describes a biologically relevant trimeric structure central to immune recognition of CEA-expressing tumors[3][7].

Other names

TCR–pMHC–CEA complexT-cell receptor–peptide MHC–CEA complex